Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

NCT02972034 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

111

Enrollment

INDUSTRY

Sponsor class

Stopped business reasons.

Conditions

Neoplasms
Colorectal Cancer

Interventions

DRUG: MK-8353
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC